Ask AI
ProCE Banner Activity

Phase IIa Trial of Once-Monthly MK-8527 as Oral PrEP in Adults at Low Risk of HIV-1 Exposure

Conference Coverage
Slideset

Six consecutive oral monthly doses of MK-8527 was found to be well tolerated across dosing levels in adults at low risk of HIV-1 exposure, preparing the way for phase III investigation.

Released: July 18, 2025

Expiration: January 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner